• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Infect Dis Ther . Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19

tetano

Editor, Senior Moderator
Infect Dis Ther


. 2021 Jun 11.
doi: 10.1007/s40121-021-00477-9. Online ahead of print.
Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19


Fernanda Meira[SUP] 1 [/SUP], Estela Moreno-García[SUP] 1 [/SUP], Laura Linares[SUP] 1 [/SUP], Irene Macaya[SUP] 1 [/SUP], Adria Tomé[SUP] 1 [/SUP], Marta Hernández-Meneses[SUP] 1 [/SUP], Laia Albiach[SUP] 1 [/SUP], Laura Morata[SUP] 1 [/SUP], Laura Letona[SUP] 1 [/SUP], Marta Bodro[SUP] 1 [/SUP], Alberto Cózar-Llistó[SUP] 1 [/SUP], Celia Cardozo[SUP] 1 [/SUP], Mariana Chumbita[SUP] 1 [/SUP], Cristina Pitart[SUP] 2 [/SUP], Juan Ambrosioni[SUP] 1 [/SUP], Verónica Rico[SUP] 1 [/SUP], Daiana Agüero[SUP] 1 [/SUP], Pedro Puerta-Alcalde[SUP] 1 [/SUP], Nicole Garcia-Pouton[SUP] 1 [/SUP], Francesc Marco[SUP] 2 [/SUP], Carolina Garcia-Vidal[SUP] 1 [/SUP], Alex Soriano[SUP] 3 [/SUP], José Antonio Martínez[SUP] 1 [/SUP]



Affiliations

Abstract

Introduction: The study aim was to assess the influence of inflammatory response modifiers, including anti-interleukin-6 (IL-6) biologics and corticosteroids, on the incidence of hospital-acquired infections in patients with coronavirus disease 2019 (COVID-19).
Methods: Case-control study performed at a university hospital from February 26 to May 26, 2020. Cases were defined as patients with COVID-19 who developed hospital-acquired infections. For each case, two controls were selected among patients without infections. Cases and controls were matched obeying three criteria in a hierarchical sequence: length of hospital stay up until the first infection; comorbidity; and need for Intensive care unit (ICU) admission. Conditional logistic regression analysis was used to estimate the association of exposures with being a case.
Results: A total of 71 cases and 142 controls were included. Independent predictors for acquiring a hospital infection were chronic liver disease [odds ratio (OR) 16.56, 95% CI 1.87-146.5, p = 0.012], morbid obesity (OR 6.11, 95% CI 1.06-35.4, p = 0.043), current or past smoking (OR 4.15, 95% CI 1.45-11.88, p = 0.008), exposure to hydroxychloroquine (OR 0.2, 95% CI 0.041-1, p = 0.053), and invasive mechanical ventilation (OR 61.5, 95% CI 11.08-341, p ≤ 0.0001).
Conclusions: Inflammatory response modifiers had no influence on acquisition of nosocomial infections in admitted patients with COVID-19. Hospital-acquired infections primarily occurred in the critically ill and invasive mechanical ventilation was the main exposure conferring risk.

Keywords: COVID-19; Inflammatory response modifiers; Nosocomial infections; SARS-CoV-2.
 
Back
Top Bottom